Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Moderna Signs Single Drug Deal With CF Expert Vertex For Up To $315m

Executive Summary

Moderna Therapeutics LLC extended its dealmaking streak and signaled a shift for its collaborative strategy by signing a partnership with Vertex Pharmaceuticals Inc. to develop a cystic fibrosis (CF) therapy based on the private biotechnology firm's messenger RNA (mRNA)-based drug development technology.

Advertisement

Related Content

Cystic Fibrosis: Successes, Opportunities And Challenges
Biopharma Unicorn Moderna Highlights Secretive Pipeline As Investors Await IPO
Moderna Prepares For mRNA Drug R&D Blitz With $474m In New Equity
VC Roundup: Moderna Seeks Another Record-Breaking Raise; Arcus Emerges From Stealth Mode
Merck Bets Moderna's Cancer Vaccines Can Prime Patients For Immunotherapy
AstraZeneca Ups Betting Ante On Moderna's Messenger RNA Technology
Vertex Gears Up For Next Generation In CF Therapy
Gene Editing Deal Broadens Vertex's CF Base, Doubles CRISPR's Cash
Moderna raises $450m; most ever for private biotech

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065603

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel